DHR Stock Recent News

Explore how Danaher's (DHR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

'Mad Money' host Jim Cramer talks how to play Danaher after earnings.

While the worst seem to be behind them, the business isn't quite humming enough to get investors excited yet. Revenue growth guidance for 2025 remains unchanged at 3%. But they did raise full year adjusted diluted net EPS guidance to a range of $7.70 to $7.80 vs previous range of $7.60 to $7.75. Compared to the past few years, Danaher's multiples have noticeably come down. However, it is hard for a stock to go up if revenue growth hovers around LSD level.

Investors interested in Medical Services stocks are likely familiar with CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Danaher Corporation is returning to growth, led by strong bioprocessing demand and resilient diagnostics, with Life Sciences expected to recover in late 2025. Margins may face short-term pressure, but a $150M cost-reduction plan and easing China headwinds should drive margin expansion from FY26 onward. The stock trades at a meaningful discount to historical valuation, offering compelling upside as earnings growth is set to reaccelerate post-FY25.

Danaher (DHR 0.98%) reported its second-quarter 2025 results on July 22, 2025, with sales of $5.9 billion and core revenue growth of 1.5% year over year. Adjusted diluted EPS grew 5% to $1.80, free cash flow hit $1.1 billion, and management raised full-year adjusted diluted net EPS guidance to $7.70–$7.80.

Global science and technology innovator Danaher (DHR 1.08%) reported second quarter 2025 results on Tuesday, July 22, that topped analysts' consensus expectations. Q2 revenue of $5.94 billion came in above the $5.84 billion estimate, and adjusted EPS reached $1.80 versus the $1.64 analysts expected.

Danaher Corporation (NYSE:DHR ) Q2 2025 Earnings Conference Call July 22, 2025 8:00 AM ET Company Participants John Bedford - Vice President of Investor Relations Matthew R. McGrew - CFO & Executive VP Rainer M.

DHR tops Q2 estimates with strong sales across segments, lifting its 2025 EPS outlook amid mixed margin trends.